This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moskowitz, M. A. Articles by Waeber, C. Search for Related Content PubMed Articles by Moskowitz, M. A. Articles by Waeber, C. Social Bookmarking                   What's this?

Migraine Enters the Molecular Era

Stroke and Neurovascular Regulation Laboratory Departments of Neurosurgery and Neurology Harvard Medical School Massachusetts General Hospital Charlestown, Massachusetts

Christian Waeber

Stroke and Neurovascular Regulation Laboratory Departments of Neurosurgery and Neurology Harvard Medical School Massachusetts General Hospital Charlestown, Massachusetts

Migraine headache is the first neurological condition treatable by a drug targeted to a specific receptor binding site. Originally viewed as a disorder of brain blood vessels, migraine may have as its biological basis a disturbance in brain function. Regarding therapy, recent molecular data document that 5-HT_1D receptors on primary afferent fibers are coupled to inhibition of neuropeptide release, blockade of neurogenic inflammation, and c-fos expression within the trigeminal nucleus caudalis after noxious meningeal stimulation in experimental animals. The 5-HT_1D receptor subtype (as opposed to the 5-HT _1Dß receptor) has emerged as an important therapeutic target aimed at blocking trigeminal nerve fibers without constricting vascular smooth muscle. NEUROSCIENTIST 2:191-200, 1996

Key Words: KEY WORDS Trigemmovascular system • 5-HT1D receptors

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Bolay and M. A. Moskowitz Mechanisms of pain modulation in chronic syndromes Neurology, September 10, 2002; 59(90052): S2 - 7. [Abstract] [Full Text]

				M. L. Cohen and K. Schenck 5-Hydroxytryptamine1F Receptors Do Not Participate in Vasoconstriction: Lack of Vasoconstriction to LY344864, a Selective Serotonin1F Receptor Agonist in Rabbit Saphenous Vein J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 935 - 939. [Abstract] [Full Text]